The investigators hypothesize that the addition of Tislelizumab after definitive local therapy for locally advanced inoperable Hepatocellular carcinoma (HCC) w…

Carcinoma, HepatocellularLiver Cell Carcinoma

~Estimated

~$10 – $6,250

Rutgers, The State University of New JerseyNCT05366829

Phase 1

Immunotherapy for Solid Tumor Malignancies in Pediatrics Using Interleukin-15 and -21 Armored Glypican-3-specific Chimeric Antigen Receptor T Cells

This Phase 1, open-label, non-randomized study will enroll pediatric and young adult subjects with relapsed or refractory non-central nervous system (CNS) mali…

Solid Tumor (Excluding CNS)Liver Cell CarcinomaMalignant Rhabdoid Tumor+7 more

~Estimated

~$10 – $6,250

Seattle Children's HospitalNCT07148050

Phase 1

INTERCEPT-GPC3: Interleukin-15 and -21 Armored Glypican-3 Specific Chimeric Antigen Receptor Expressing Autologous T-cells in Adults With GPC3-positive Solid Tumors

This Phase 1, open-label, non-randomized study will enroll adult subjects with relapsed or refractory non-central nervous system (CNS) malignant solid tumors e…

Solid Tumor (Excluding CNS)Hepatocellular CarcinomaLiver Cell Carcinoma+3 more

~Estimated

~$10 – $6,250

Seattle Children's HospitalNCT07224568